GlobeImmune Inc (NASDAQ:GBIM) Investor Investigation Concerning Potential Securities Laws Violations Announced

If you purchased shares of GlobeImmune Inc (NASDAQ:GBIM), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
GlobeImmune
Affected Securities: 
NASDAQ: GBIM

June 15, 2015 (Shareholders Foundation) - An investigation on behalf of investors of GlobeImmune Inc (NASDAQ:GBIM) shares over potential securities laws violations by GlobeImmune and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of GlobeImmune Inc (NASDAQ:GBIM) concerning whether a series of statements by GlobeImmune regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

GlobeImmune Inc went public in July 2014 and shares of GlobeImmune Inc (NASDAQ:GBIM) reached as high as $14.79 per share in July.

On May 27, 2015, GlobeImmune Inc announced top line results from the Phase 2 trial for its hepatitis B treatment.

On June 10, 2015, G GlobeImmune Inc announced that, “it is evaluating strategic options for the company. In conjunction with this process, the Board has authorized eliminating the majority of positions in its workforce. . . Following our recent data announcement in our hepatitis B program, this workforce reduction is a necessary action to conserve working capital and provide maximum flexibility in determining the future direction of GlobeImmune.”

Shares of GlobeImmune Inc (NASDAQ:GBIM) declined to as low as $2.60 per share on June 10, 2015.